The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting
James G Ryall, Gordon S Lynch
Pharmacology and Therapeutics | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2008
Related Projects (3)
Awarded by Australian Research Council
Awarded by National Health and Medical Research Council of Australia
Awarded by Muscular Dystrophy Association (USA)
The funding for this research has been provided by generous grants from the Australian Research Council Discovery-Project funding scheme (DP0665071, DP0772781), the National Health and Medical Research Council of Australia (350439, 454561, 509313), the Muscular Dystrophy Association (USA, 3595,4167), Pfizer Inc. (USA), and Merck & Co. Inc. (USA).